How can we estimate a treatment effect when treated and untreated
patients differ at baseline? This introduction compares inverse
probability weighting, outcome-model standardization, and doubly robust
estimation. It then shows how to use precmed for a binary
outcome. For the formulas and outcome-specific assumptions, see Methods for estimating average treatment
effects.
The question and the models
Suppose the outcome is whether a patient has a relapse during one year. We want the population-average risk difference: the proportion who would relapse if everyone received treatment 1 minus the proportion who would relapse if everyone received treatment 0. A negative difference means fewer relapses under treatment 1. This marginal effect is distinct from a treatment effect conditional on a particular patient’s covariates.
In observational data, the observed difference in relapse proportions may reflect differences in baseline characteristics as well as treatment. Two approaches can help adjust for measured covariates:
- Inverse probability weighting (IPW) uses a treatment model to estimate each patient’s propensity score: the probability of receiving treatment 1 given their covariates. Patients receive more weight if they received a treatment that was less likely given their covariates. The weighted relapse outcomes are then compared between treatment groups. Propensity scores can also be used for matching, stratification, or regression adjustment; see Chapter 7 for an introduction to these methods (Jiang et al. 2026).
- Outcome-model standardization, also called g-computation, uses an outcome model to predict relapse given treatment and covariates. For each patient in the target population, the model predicts the probability of relapse under treatment 0 and again under treatment 1, using the patient’s observed covariates. Averaging the predictions separately for each treatment gives two estimated population-average risks; their difference estimates the risk difference. For example, average predicted risks of 20% under treatment 0 and 15% under treatment 1 give a risk difference of -5 percentage points.
Both approaches need causal identification assumptions, including well-defined treatments and consistency, no unmeasured treatment–outcome confounding given the adjustment covariates, and positivity: each treatment must be possible at relevant covariate values. They also need suitable modeling and regularity assumptions. Outcome-model standardization generally relies on a correctly specified outcome model, whereas IPW relies on a correctly specified treatment model. These are sometimes called singly robust approaches with respect to model misspecification.
What does doubly robust mean?
A doubly robust estimator combines the outcome and treatment models in a particular way. For example, augmented inverse probability weighting (AIPW) starts with outcome-model predictions and adds a propensity-weighted correction based on the observed prediction errors. Under the identification and relevant regularity assumptions, this estimator is consistent if either the outcome model or the treatment model is correctly specified; both may be correct (Kurz 2022). Merely fitting two models does not make an estimator doubly robust.
| Outcome model | Treatment model | AIPW consistency under the other assumptions |
|---|---|---|
| Correct | Correct | Yes |
| Correct | Incorrect | Yes |
| Incorrect | Correct | Yes |
| Incorrect | Incorrect | Not guaranteed |
This is an asymptotic property, not a promise of negligible bias in a finite sample or valid confidence intervals without further conditions. Double robustness does not fix unmeasured confounding, poor overlap, measurement errors, or misspecification of both models. Extreme propensity scores can make estimates unstable. Truncating propensity scores may improve stability, but if it changes the true probabilities it can remove the guarantee based solely on a correct treatment model. Examine overlap and model plausibility rather than treating double robustness as a substitute for study design.
An example with a binary outcome
The following synthetic example compares three estimates of the same population-average risk difference, treatment 1 minus treatment 0, for relapse within one year. Treatment assignment depends on age and previous treatment. The outcome is fully observed. The simulation is illustrative, not a clinical estimate; its treatment model is correctly specified by construction, while the generated outcome need not follow the logistic outcome model exactly. A single simulated dataset cannot establish which estimator is unbiased.
library(precmed)
dat <- simulate_binary(n = 4000, seed = 2026, followup = 1, threshold = 0)
table(dat$trt)
#>
#> drug0 drug1
#> 1858 2142First, fit a logistic outcome model and average predictions for the
same patients under each treatment. Then fit a logistic treatment model
and calculate IPW means. These are illustrative base R calculations, not
separate precmed estimators. We include treatment
interactions in the outcome model and use the same covariates in both
approaches below.
outcome_fit <- glm(y ~ trt * (age + previous_treatment),
data = dat, family = binomial())
treatment_fit <- glm(trt ~ age + previous_treatment,
data = dat, family = binomial())
under_0 <- under_1 <- dat
under_0$trt <- factor("drug0", levels = levels(dat$trt))
under_1$trt <- factor("drug1", levels = levels(dat$trt))
standardized <- mean(predict(outcome_fit, under_1, type = "response")) -
mean(predict(outcome_fit, under_0, type = "response"))
# Match the default propensity-score limits used by atefit().
ps <- pmin(pmax(predict(treatment_fit, type = "response"), 0.01), 0.99)
treated <- dat$trt == "drug1"
ipw <- mean(treated * dat$y / ps) - mean((!treated) * dat$y / (1 - ps))Now fit the doubly robust AIPW estimator with atefit().
outcome_model specifies the outcome and covariates; by
default, atefit() fits a separate logistic outcome model
for each treatment arm. ps_model specifies the treatment
model. The 100 bootstrap replicates keep this example quick; use more
for a substantive analysis and examine bootstrap diagnostics.
fit <- atefit(response = "binary", data = dat,
outcome_model = y ~ age + previous_treatment,
ps_model = trt ~ age + previous_treatment,
outcome_method = "logistic", n.boot = 100, seed = 999)
c(outcome_standardization = standardized, ipw = ipw,
doubly_robust = unname(fit$risk.difference$estimate))
#> outcome_standardization ipw doubly_robust
#> -0.10298071 -0.09978176 -0.10762720
confint(fit)
#> 2.5 % 97.5 %
#> risk.difference -0.1464453 -0.06880907The estimates need not agree in a finite sample, even when the
necessary assumptions hold. The displayed confidence interval applies to
the atefit() estimate, not the two illustrative
calculations. A confidence interval describes sampling uncertainty under
the procedure; it does not account for unmeasured confounding or
establish that either model is correct.
Choosing and using a method
Doubly robust estimation can be useful when there is uncertainty about the correct specification of the outcome and treatment models. A singly robust approach, such as outcome-model standardization or inverse probability weighting, generally relies on correct specification of its respective model. A doubly robust estimator such as AIPW is consistent if either the outcome model or the treatment model is correctly specified, provided the required causal identification and regularity assumptions also hold. Note that doubly robust methods do not protect against unmeasured confounding, poor treatment overlap, or misspecification of both models.
Doubly robust estimation is not automatically more accurate in every dataset. Specify both models carefully using subject-matter knowledge, inspect treatment overlap and extreme weights, assess model fit and sensitivity to modeling choices, and report the target population and effect scale. Randomization can support exchangeability, but overlap and other assumptions still matter. For a simple randomized trial, an intercept-only treatment model may be appropriate; account for the actual assignment design when choosing it.
In precmed, atefit() estimates a marginal
risk difference for binary outcomes, a marginal rate ratio for count
outcomes, and, for survival outcomes at a chosen horizon, a marginal
restricted mean time lost ratio, cumulative hazard ratio, and event risk
difference (treatment 1 minus treatment 0). The catefit()
methods instead construct covariate-conditional treatment-effect scores;
some scoring methods are doubly robust, while others use different
approaches. Score fitting and subsequent validation are distinct tasks,
and an ATE estimate or its bootstrap interval is not validation of a
CATE score. See Methods for
developing and validating CATE scores for method-specific details
and assumptions.
For survival outcomes, precmed also uses a
censoring model to supply probabilities for inverse
probability of censoring weighting (IPCW). Double robustness with
respect to the outcome and treatment models does not protect against a
misspecified censoring model. The estimand and support at the chosen
survival horizon matter too. For example, an out-of-range restricted
mean survival estimate may trigger an outcome-model fallback that does
not retain the doubly robust guarantee. See Methods for estimating average treatment
effects for these qualifications and the survival estimands.

